David R. Parkinson, MD; Malcolm A. Smith, MD, PhD
In this issue of Annals, Frankel and colleagues (1) describe a syndrome that developed in patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid (1). The description of this dramatic syndrome provides an opportunity to review the larger significance of a remarkable new class of drugs, retinoids, and of differentiation therapy for malignancy.
The unfolding story of the use of retinoic acid for successful remission induction in patients with acute promyelocytic leukemia is instructive and is a confirmation of the coming of age of the differentiation therapy of malignancy. Long a goal of cancer therapists, it is
David R. Parkinson, Malcolm A. Smith. Retinoid Therapy for Acute Promyelocytic Leukemia: A Coming of Age for the Differentiation Therapy of Malignancy. Ann Intern Med. 1992;117:338–340. doi: 10.7326/0003-4819-117-4-338
Download citation file:
Published: Ann Intern Med. 1992;117(4):338-340.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use